Check-Cap (NASDAQ:CHEK) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Check-Cap (NASDAQ:CHEKFree Report) in a report issued on Wednesday. The brokerage issued a sell rating on the medical research company’s stock.

Check-Cap Trading Up 3.2 %

NASDAQ CHEK opened at $1.93 on Wednesday. The company has a fifty day simple moving average of $2.13 and a 200 day simple moving average of $2.82. Check-Cap has a 12-month low of $1.22 and a 12-month high of $4.63. The company has a market cap of $11.29 million, a P/E ratio of -0.64 and a beta of 0.21.

Hedge Funds Weigh In On Check-Cap

Hedge funds have recently bought and sold shares of the company. Dimensional Fund Advisors LP purchased a new position in Check-Cap during the 4th quarter worth $31,000. Citadel Advisors LLC boosted its holdings in Check-Cap by 51.2% during the 3rd quarter. Citadel Advisors LLC now owns 141,319 shares of the medical research company’s stock worth $41,000 after acquiring an additional 47,868 shares during the last quarter. Susquehanna International Group LLP purchased a new position in Check-Cap during the 1st quarter worth $57,000. Virtu Financial LLC boosted its holdings in Check-Cap by 363.4% during the 2nd quarter. Virtu Financial LLC now owns 224,696 shares of the medical research company’s stock worth $69,000 after acquiring an additional 176,207 shares during the last quarter. Finally, Nantahala Capital Management LLC purchased a new position in Check-Cap during the 4th quarter worth $69,000. 0.21% of the stock is owned by hedge funds and other institutional investors.

About Check-Cap

(Get Free Report)

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.

Further Reading

Receive News & Ratings for Check-Cap Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check-Cap and related companies with MarketBeat.com's FREE daily email newsletter.